Research programme: alphaV-beta3 receptor antagonists - Shire

Drug Profile

Research programme: alphaV-beta3 receptor antagonists - Shire

Latest Information Update: 12 Dec 2007

Price : $50

At a glance

  • Originator Beth Israel Deaconess Medical Center; Shire Pharmaceuticals Group
  • Developer CliniChem Development
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Macular degeneration

Most Recent Events

  • 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
  • 08 Dec 1998 Preclinical development for Cancer in Canada (Unknown route)
  • 08 Dec 1998 Preclinical development for Macular degeneration in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top